Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Journey Medical CorporationNASDAQ: DERM

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $60K. Over 3 fiscal years it compounded at -1.6% a year.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $15K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$60K-1.6% YoY
LTMMar 2026
$60K-1.6% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-1.6%——
3-year CAGR-1.6%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
60K USD
Year-over-year change
-1.6%
4-year CAGR
-56.2%

Income Tax Expense vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.6% is the 3rd highest of 8, against a peer median of -71.0%.
  • Income tax expense amounts to 0.1% of revenue for DERM, versus a peer median of 1.0%.
DERM Competitors
Income Tax Expense for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSUROraSure Technologies, Inc.LTM Mar 2026$1.83M USD+34.1%+7.3%1.6%
NYXHNyxoah S.A.LTM Mar 2026€1.33M EUR-52.7%-4.8%8.2%
MDWDMediWound Ltd.LTM Mar 2026$147K USD+250.0%+29.4%1.0%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$106K USD-71.0%—0.2%
DERMJourney Medical CorporationLTM Mar 2026$60K USD-1.6%-1.6%0.1%
IVAInventiva S.A.FY2025€22K EUR-93.0%—0.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$0 USD——0.0%
HSDTSolana CompanyLTM Mar 2026$0 USD——0.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$9.19M USD-3303.1%—517.9%
OGIOrganigram Global Inc.LTM Mar 2026-CA$13.66M CAD-29804.3%—5.0%
Peer median (excluding DERM) —-71.0%+7.3%1.0%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.